Iontophoretic EGP-437 shows positive early results in treatment of postop ocular inflammation, pain

Iontophoretic EGP-437 showed positive early results in a phase 1b/2a trial evaluating the treatment of ocular inflammation and pain after cataract surgery, EyeGate Pharmaceuticals announced in a press release.

The trial included 40 patients who underwent cataract surgery with posterior chamber IOL implantation. Patients were assigned to one of four cohorts and administered iontophoretic EGP-437 at 9 mA-min or 14 mA-min on day 0, day 1 and day 2 or day 0, day 1 and day 4 with the potential for additional treatment on day 7 in all four cohorts.

At day 28, the most significant improvement in anterior chamber cell count was seen in patients receiving the 14 mA-min dose on days 0, 1 and 4; anterior chamber cell count was 0 in 40% of patients in the cohort at 14 days and in 88% of patients at 28 days.

All patients had a reduction in pain at all time points; 90% of patients who received the 14 mA-min dose on days 0, 1 and 4 had no pain on day 1 and 100% had no pain on day 14.

The treatment was well tolerated, and no steroid-related increase in IOP was seen.

Three new cohorts that are receiving varying doses and dosing regimens have since been added to the ongoing trial. Top-line data from the new cohorts are expected to be released in the fourth quarter, the release said. EyeGate plans to initiate a randomized, placebo-controlled trial of iontophoretic EGP-437 by the end of the year.